Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 6/20 | 0.43 |
| ▸ | FAAH | O00519 | 5/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.35 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.35 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24131221 | 0.91 | MGLL (0.42) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL11690853 | 0.86 | SMN1; SMN2 (0.40) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL221915 | 0.81 | MGLL (0.46) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL9811510 | 0.81 | MGLL (0.37) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL8652814 | 0.79 | MGLL (0.47) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL8803997 | 0.78 | PLA2G2A (0.47) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL12101786 | 0.78 | MGLL (0.46) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL5570285 | 0.78 | MGLL (0.50) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL10816291 | 0.76 | MGLL (0.40) | MGLLFAAHPTGS1PTGS2ALDH1A1 | |
| SCHEMBL27596669 | 0.76 | HDAC6 (0.41) | MGLLFAAHPTGS1PTGS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 299 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115403624-A | Diaryl thiohydantoin compound and preparation method and application thereof | 上海应用技术大学 | 2022-11-29 | — | — | CN | claimed |
| US-20220186227-A1 | Therapeutic Targets for Oncogenic KRAS-Dependent Cancers | UNIVERSITY OF MASSACHUSETTS | 2022-06-16 | — | — | US | claimed |
| EP-3946629-A1 | THERAPEUTIC TARGETS FOR ONCOGENIC KRAS-DEPENDENT CANCERS | University Of Massachusetts (US) | 2022-02-09 | — | — | EP | claimed |
| WO-2020198488-A1 | THERAPEUTIC TARGETS FOR ONCOGENIC KRAS-DEPENDENT CANCERS | UNIVERSITY OF MASSACHUSETTS (US) | 2020-10-01 | — | — | WO | claimed |
| EP-3329775-A1 | PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS | Medivation Prostate Therapeutics LLC (US) | 2018-06-06 | — | — | EP | claimed |
| EP-3020706-A1 | DIARYLTHIOHYDANTOIN COMPOUNDS USEFUL FOR THE TREATMENT OF A HYPERPROLIFERATIVE DISORDER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-05-18 | — | — | EP | claimed |
| US-9205102-B2 | Method for treatment of castration-resistant prostate cancer | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-12-08 | — | — | US | claimed |
| US-9174943-B2 | Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2015-11-03 | — | — | US | claimed |
| US-20150157656-A1 | Method for Treatment of Castration-Resistant Prostate Cancer | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-06-11 | — | — | US | claimed |
| WO-2015042170-A1 | COMPOSITIONS AND USES OF COMBINATIONS OF DIM-RELATED INDOLES AND SELECTED ANTI-ANDROGEN COMPOUNDS | WAYNE STATE UNIVERSITY (US) | 2015-03-26 | — | — | WO | claimed |
| US-20130190507-A1 | PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS LLC | 2013-07-25 | — | — | US | claimed |
| EP-2538785-A1 | PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS | Medivation Prostate Therapeutics, Inc. (US) | 2013-01-02 | — | — | EP | claimed |
| US-8110594-B2 | Diarylthiohydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-07 | — | — | US | claimed |
| WO-2011106570-A1 | PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS | MEDIVATION PROSTATE THERAPEUTICS, INC. (US) | 2011-09-01 | — | — | WO | claimed |
| CN-101460467-A | Diarylthiohydantoin compounds | UNIV CALIFORNIA (US) | 2009-06-17 | — | — | CN | claimed |
| EP-2013187-A2 | DIARYLTHIOHYDANTOIN COMPOUNDS | The Regents of the University of California (US) | 2009-01-14 | — | — | EP | claimed |
| US-20080139634-A2 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; androgen receptor antagonists with minimal agonist activity | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-06-12 | — | — | US | claimed |
| WO-2007127010-A9 | DIARYLTHIOHYDANTOIN COMPOUNDS | UNIV CALIFORNIA (US) | 2008-05-22 | — | — | WO | claimed |
| WO-2007127010-A2 | DIARYLTHIOHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-08 | — | — | WO | claimed |
| US-20070254933-A1 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; selective androgen receptor modulators; non-steroidal, non-toxic, and tissue selective | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139634-A2 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; androgen receptor antagonists with minimal agonist activity | AR, LHCGR, KLK3 | MGLL 4459/4885FAAH 1535/4885PTGS1 600/4885 |
| US-20070254933-A1 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; selective androgen receptor modulators; non-steroidal, non-toxic, and tissue selective | AR, NR5A1, SHBG | MGLL 4758/4885FAAH 2125/4885PTGS1 164/4885 |
| US-20150157656-A1 | Method for Treatment of Castration-Resistant Prostate Cancer | IGFBP5, IGFBP2, IGFBP1 | MGLL 4543/4885FAAH 4601/4885PTGS1 4310/4885 |
| US-20130190507-A1 | PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS | BPHL, PTMS, DHPS | MGLL 1156/4885FAAH 33/4885PTGS1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.